Cooperative Agreement U01CA290680
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $703K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, USA
Similar Awards
- This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $531,693.00 to the University of Southern California to conduct research aimed at improving immunotherapy treatments for breast cancer. The project will develop a computational model to understand the interactions between breast tumors and the immune system, with the goal of identifying new strategies to enhance the efficacy of immunotherapies. Key activities include...
- The University of Texas MD Anderson Cancer Center was awarded a $597,289 Cooperative Agreement from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) on July 9, 2025. The objective of this project is to develop a chimeric RNA-driven neopeptide vaccine for the prevention of breast cancer in individuals with germline BRCA1/2 mutations. The research aims to identify and validate MHC Class I immunogenic peptides generated from chimeric mRNA transcripts that can serve...
- The National Cancer Institute (NCI) awarded a $825,857 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Health Research, Inc. at Roswell Park Comprehensive Cancer Center. The goal of this 5-year award is to catalyze collaboration across the Cancer Immunoprevention Network (CIP-NET) and manage, integrate, and disseminate the data and resources generated by the network. Key objectives include fostering a collaborative research community, providing...
- This $462,092 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is focused on investigating novel immune checkpoint targets for the topical immunoprevention of keratinocytic skin cancer. The award is held by the University of Arizona and will run from August 1, 2025 to July 31, 2027. The key objectives of the project are to 1) use human samples to identify novel immune checkpoint proteins that are upregulated early in the skin...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
- This $5,041,790 cooperative agreement award from the National Cancer Institute (NCI), under the Cancer Centers Support Grants program (CFDA 93.397), will fund research projects at the University of California, San Francisco (UCSF) to improve cancer health disparities. The key products and services to be delivered include: Three translational cancer health disparities research projects focused on meningioma, prostate cancer, and breast cancer. The projects aim to evaluate the interplay of...
- This $251,360 Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research by Yale University to develop and validate multiplexed quantitative immunofluorescence (MQIF) assays. The goal is to measure key immune response metrics and homologous recombination-deficiency (HRD) proteins in tumor biopsies. This research aims to expand the repertoire of predictive biomarkers for cancer treatments like PD-1 axis blockers and...
- This Cooperative Agreement award for $639,882, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at the University of North Carolina at Chapel Hill to elucidate the molecular mechanisms of metastasis organ tropism in breast cancer. The key objectives are to: Identify molecular determinants of lung and liver organ-specific metastasis using a comprehensive dataset of human primary tumors and metastases, as well as genetically...
- This federal Project Grant award of $156,500, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a study titled "Nurses Surviving Breast Cancer: An Exploration of Breast Cancer Diagnosis, Reported Lymphedema Symptoms, and Lifestyle Status in the Nurses' Health Study Survey". The study aims to 1) explore patterns of incidence of self-reported breast cancer-related lymphedema (BCRL) symptoms, and 2) examine...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $216,682 to The Trustees of the University of Pennsylvania to develop "tumor-site activated T cell redirecting autoantibodies" - a novel cancer immunotherapy approach. The award period runs from March 1, 2025 to February 28, 2027. The project aims to leverage a patient's own anti-tumor autoantibodies to enhance the immune system's ability to target and clear cancer cells,...